Since the news of a potential Ebola outbreak in the US came out, Ebola stocks have been very volatile this past month as they have gotten a lot of attention among investors and traders this past month.
Any company related to Ebola has risen dramatically. Various companies such as biotech companies and companies that make hazmat suits have all risen. Some Ebola stocks doubled and tripled in value in only a few days.
Here are 5 Ebola stocks to trade if the Ebola frenzy continues.
1. Sanomedics International Holdings (SIMH)
Sanomedics International manufactures innovative medical devices and provides other health benefits including preventive medicines. The company has recently been getting attention due to the Ebola penetration in the country. The company’s latest product is a non-contact thermometer, which can record a person’s temperature in a matter of seconds without any physical contact.
The product was given coverage by a Miami-based tv station, which demonstrated how it could be used with Ebola-infected patients. The company mentioned in its latest press release that it has received an order for a 100 of these thermometers, which will be distributed at the country’s major airports with the help of the Center for Disease Control (CDC). In addition to that, the video revealed that 80 of those 100 thermometers were ordered by the CDC; 20 were ordered by a West African company.
Sanomedics International is a penny stock that trades over the counter. Before the Ebola panic (before Oct. 6th), SIMH was trading at $0.03 per share. The stock shot up to $.60 per share on October 13th for a 2300% gain in only a few days. The stock has since fallen back to $0.07, but if the Ebola frenzy continues, look for this stock to continue to rise again.
2. IBIO Inc (IBIO)
IBIO is a maker of a technology that speeds up production of a drug called ZMapp, which has proven to be effective in treating the Ebola virus
The drug is manufactured using tobacco plants, and has been administered to two Ebola-afflicted Americans, a Spanish priest, and three Liberian health workers. It is one of the most advanced anti-Ebola drugs to have been produced so far. Its supply, however, has been exhausted.
Ibio recently announced that it will provide the US government with its iBioLaunch technology to speed up ZMapp’s production. This has helped the stock to climb very fast. The stock went from $.75 (October 6th) to $3.48 (October 17th).
3. Lakeland Industries (LAKE)
Lakeland Industries is a NASDAQ listed stocks. The company manufactures and sells a line of safety garments and accessories for the industrial protective clothing markets. The company’s protective gears and hazmat suits are considered the best in the industry for healthcare workers tending to Ebola patients
In a recent announcement the company said the United States Department placed a bid for 160,000 protective suits. It is also expected that the orders for the hazmat suits will increase following the confirmation of the first Ebola case in the U.S.
LAKE is a low float stock and can get very volatile. The stock quickly rose from $8.65 (October 6th) and hit a high of $32.76 (October 13th).
4. Alpha Pro Tech (APT)
(Alpha Pro Tech) is in the business of protecting people, products and environments. The ticker has also gotten the attentions of investors and traders because it is also involved in supplying hazmat suits similar to LAKE.
APT has risen from $3.15 (October 6th) to a high of $10.74 (October 13th).
5. Tekmira Pharmaceuticals (TKMR)
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company. Tekmira has a diverse pipeline of products in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company trades on the NASDAQ and is the maker the TKM-Ebola drug, which is currently in testing phases.
TKM-Ebola, an anti-Ebola virus RNAi therapeutic, is being developed under a $140 million contract with the U.S. Department of Defense’s Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office. Earlier preclinical studies were published in the medical journal The Lancet and demonstrated that when siRNA targeting the Ebola virus and delivered by Tekmira’s LNP technology were used to treat previously infected non-human primates, the result was 100 percent protection from an otherwise lethal dose of Zaire Ebola virus. In March 2014, Tekmira was granted a Fast Track designation from the U.S. Food and Drug Administration for the development of TKM-Ebola.